Pathway awards are available by institutional nomination only

Candidates will be identified through nominations from U.S.-accredited academic and nonprofit research institutions.

Each institution is allowed a maximum of one nomination. The nomination can be in one of the three available Pathway award types:

Nominations must be on behalf of the institution and from an authorized institutional representative, such as the Nominating Committee Chair, Division Chair, Dean of Research, or President. Individual components of multi-component institutions (e.g. University of California Los Angeles and University of California Berkeley within the University of California system, or Harvard University and Beth Israel Deaconess Medical Center within the Harvard system) are sufficiently independent to be considered individual institutions. Institutions must have a unique DUNS and or IPF number to be considered independent.

Pathway seeks exceptional nominees from a broad range of disciplines, including medicine, biology, chemistry, engineering, mathematics and physics.

The Pathway program is highly competitive. Over the first two years of the program, the overall success rate for applications to the program has been approximately 5%. Success rates vary significantly depending on award mechanism, with Visionary (previously Accelerator New to Diabetes) being the most competitive with only a 2% success rate, Accelerator (previously Accelerator Early Investiagor) with a 5% success rate and Initiator with a 14% success rate.

The American Diabetes Association encourages nomination of individuals from diverse backgrounds, which includes minorities that are underrepresented in biomedical research. For the purpose of this program, underrepresented minorities are defined as individuals of African American or Black, Hispanic or Latino, American Indian, Alaskan Native, and Pacific Islander.

The 2015 Call for Nominations is now open. Application Deadline July 1, 2015.